They go the extra mile, add that personal touch…
Instem Life Science Systems plc has trading entities in Europe, China and the USA. Day-to-day activities are conducted as a single, seamless entity known as Instem, with the corporate structure deliberately invisible internally and externally.
Our corporate strategy has been founded on establishing a level of market penetration for our solutions that ensures we are consistently profitable and cash generative, enabling us to make the level of ongoing product and service investment that maintains an unquestionable leadership position. Our Provantis PreClinical Safety Data Management application is a perfect example, achieving its strong market position through an exceptional team responsible for:
Instem has very robust governance structures and processes with a team of professional advisors capable of supporting our long term growth.
Continuous organic growth is anticipated in our established niche market through:
Our pricing, revenue recognition and policy of expensing much of our development efforts have resulted in a substantial recurring revenue stream, with low volatility and a strong growth in earnings and cash generation. Our cash generation has enabled us to make significant product investments, fund multiple acquisitions and execute a significant management buy-out, all of which help ensure that we retain strong investor commitment to our strategy. Our position has been strengthened yet further through our recent placing of shares and admission to trading on the AIM market of the London Stock Exchange. We will continue to explore acquisition opportunities that enhance our market position and introduce complementary solutions to our portfolio by maintaining an agile organization that has the ability to respond to opportunities anywhere in the world.
For further financial and investor information, please visit our Investor Center.